文献速递骨质疏松与代谢性骨病

双膦酸盐与糖尿病风险及血糖控制的相关性:一项Meta分析

Association of bisphosphonates with diabetes risk and glycemic control: a meta-analysis.
PubMed 文献 · Osteoporos Int · 2022-12-05

该Meta分析纳入7项研究共1,233,844名参与者,评估双膦酸盐对血糖控制和糖尿病风险的影响。结果显示双膦酸盐使用与糖尿病风险显著降低相关(RR=0.77),但在随机对照试验事后分析亚组中关联不显著(RR=0.93)。对空腹血糖和糖化血红蛋白的汇总分析均未显示显著关联,因异质性高且结果不一致,需进一步严谨的随机对照试验确定因果关系。

要点

  • 双膦酸盐使用与糖尿病风险显著降低相关(RR=0.77,95%CI 0.65-0.90),但随机对照试验事后分析亚组中不显著(RR=0.93,95%CI 0.74-1.18)。
  • 双膦酸盐与空腹血糖变化(WMD=-0.61 mg/dL,95%CI -2.72至1.49)及糖化血红蛋白变化(WMD=-0.11%,95%CI -0.23至0.01)均无显著关联。
  • 因研究间异质性高且随机对照试验事后分析与观察性研究结果不一致,需进一步严谨的随机对照试验确定因果关系。

核心结论

  • 服用双膦酸盐的患者相比未服用者可能有较低的糖尿病发生风险。
  • 由于研究间异质性高且随机对照试验事后分析与观察性研究结果不一致,需进一步严谨的随机对照试验确定该发现是否具有因果关系。

研究设计与样本

  • 检索MEDLINE、Embase和Cochrane Library自建库至2022年2月15日,纳入比较使用与不使用双膦酸盐时空腹血糖、糖化血红蛋白水平及糖尿病风险的实验性或观察性研究。
  • 排除无相关结局、仅提供粗估计或无对照组的研究,由两名评价者独立筛选文献、提取数据并评价研究质量,采用随机效应模型计算合并相对风险(RR)和加权均数差(WMD)。

主要发现

  • 共纳入7项关于糖尿病风险的研究(n=1,233,844),包括2项随机对照试验事后分析和5项观察性研究,双膦酸盐组相比对照组糖尿病风险显著降低(RR=0.77;95%CI 0.65至0.90;P=0.002)。
  • 在随机对照试验事后分析亚组中,双膦酸盐与糖尿病风险的关联不显著(RR=0.93;95%CI 0.74至1.18;P=0.576)。
  • 纳入3项关于空腹血糖的研究(n=4906)和1项关于糖化血红蛋白的研究(n=60),双膦酸盐与空腹血糖变化(WMD=-0.61 mg/dL;95%CI -2.72至1.49;P=0.567)及糖化血红蛋白变化(WMD=-0.11%;95%CI -0.23至0.01;P=0.083)均无显著关联。

局限性

  • 研究间异质性高。
  • 随机对照试验事后分析与观察性研究结果不一致。
  • 需进一步严谨的随机对照试验确定因果关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Previous evidence suggests that bisphosphonates may improve glycemic control. The present meta-analysis, comprising seven studies with 1,233,844 participants, demonstrated that bisphosphonate use was significantly associated with a lower risk of diabetes. However, in the randomized controlled trial subgroup, a non-significant association was found. Further studies are needed to determine causality. PURPOSE: This study aimed to evaluate the impact of bisphosphonates on glycemic control and the risk of incident diabetes. METHODS: MEDLINE, Embase, and Cochrane Library were searched from inception to February 15, 2022. Experimental or observational studies that compared fasting blood glucose (FBG) and glycated hemoglobin (HbA1c) levels and the diabetes risk with and without bisphosphonates were included. Studies without relevant outcomes, only providing crude estimates, or the absence of a control group were excluded. Two reviewers independently screened the articles, extracted data, and appraised studies. The pooled relative risk (RR) and weighted mean difference (WMD) were calculated using random effects models. RESULTS: Seven studies (n = 1,233,844) on diabetes risk were included, including two post hoc analyses of randomized controlled trials (RCTs) and five observational studies. Compared with controls, bisphosphonates (BPs) were associated with a significant decrease in the risk of diabetes (RR = 0.77; 95% CI, 0.65 to 0.90; P = 0.002). However, in the subgroup of post hoc analyses of RCTs, the association was non-significant (RR = 0.93; 95% CI, 0.74 to 1.18; P = 0.576). Moreover, three studies (n = 4906) on FBG and one (n = 60) on HbA1c were included. We observed non-significant association between BPs and changes in FBG (WMD = - 0.61 mg/dL; 95% CI, - 2.72 to 1.49; P = 0.567) and HbA1c (WMD = - 0.11%; 95% CI, - 0.23 to 0.01; P = 0.083). CONCLUSION: Patients taking BPs may have a lower risk of incident diabetes than those without BPs. However, due to the high between-study heterogeneity and inconsistent findings between post hoc analyses of RCTs and observational studies, further rigorous RCTs are required to determine whether the findings are causal.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Chen PW, Su HY, Tu YK, et al. Association of bisphosphonates with diabetes risk and glycemic control: a meta-analysis. Osteoporos Int. 2022. PMID: 36464699. doi:10.1007/s00198-022-06616-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。